Research and Development is the lifeblood of our business. The epicentre around which everything else revolves.
The world population has doubled in the last 50 years from three billion to six billion. By 2050, it’s expected to reach nine billion. The medical need is great. But at AstraZeneca, we are there, meeting today’s pharmaceutical needs. Exploring solutions. Poised to conquer the challenges of the future. At the heart of our unwavering commitment to breakthrough prescription biopharmaceuticals: Research and Development (R&D) Careers.
Our 12,000 pharma scientists are united across three continents by a common goal: to get effective new medicines to those who need them as quickly and safely as possible. We provide pharmaceutical R&D jobs in our centres of excellence in the US, UK, Canada and Sweden and we are building our R&D presence in emerging markets so that we can understand and respond quickly to unmet patient needs in these regions.
Click here to learn more about our state-of-the-art R&D Centres worldwide.
Our dedication to Pharmaceutical R&D is even evident in our expenditures: each year, we invest on average over $4 billion, focusing on six therapy areas where we believe our skills and resources can have the greatest impact. These areas together represent a major worldwide burden of disease: cancer, cardiovascular/metabolic disease and respiratory, inflammatory and autoimmune disease. Alongside this, we remain active in infection and neuroscience with targeted investments in opportunities and collaborations.
A significant portion of this investment is in key capabilities to ensure we have the skills, technology and tools to deliver success throughout the medicines life-cycle:
- Predictive Science
- Personalised Healthcare
- Clinical Trial Design & Interpretation
- Payer and RWE (Real World Evidence)
Integrated small/large molecule approach
Our small molecule and biologics capabilities are not divided; in AstraZeneca and MedImmune, R&D is one truly global team. This allows us to search for solutions to unmet medical needs regardless of therapeutic modality.
Collaborations that work
We recognise that to deliver true value we need to work with the best that science can offer, and with partners who share our interests and share our passion. Our ‘new opportunities’ iMed group proactively explores opportunities to deliver externally sourced, proof-of-concept therapeutics that may expand the breadth of internal development. We have the capabilities and resources to create strategic partnerships with organisations of all shapes and sizes to complement our own efforts, and to ensure we are continually at the forefront of groundbreaking research into human disease.
Our commitment to innovation goes beyond research and development. You’ll find it in every part of our business. We invite you to explore further with the links below. There is much to discover – not the least of which is the opportunity for you to build an incredibly rewarding career.
Last reviewed: December 17, 2013